Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 15, 2019

Primary Completion Date

December 22, 2021

Study Completion Date

October 24, 2023

Conditions
Colorectal NeoplasmsNeoplasm MetastasisColonic NeoplasmsRectal Neoplasms
Interventions
DRUG

Atezolizumab

"* 1200mg IV on day1 before start of cycle 'atezolizuamb, bevacizumab + FOLFOX(Oxaliplatin, Levoleucovorin, 5-FU')~* 840mg IV D1 of C1-12 (Cycle: every 2 weeks)"

DRUG

Bevacizumab

5mg/kg IV D1 of C1-12 (Cycle: every 2 weeks) at least 5 minutes after completion of atezolizumab

DRUG

Oxaliplatin

85mg/m2 IV D1 of C1-12 (Cycle: every 2 weeks)

DRUG

Levoleucovorin

200mg/m2 IV D1 of C1-12 (Cycle: every 2 weeks)

DRUG

5-FU

"* 5-FU Bolus: 400mg/m2 IV bolus D1 of C1-12 (Cycle: every 2 weeks)~* 5-FU infusion: 2400mg/mg continuous IV infusion over 46hours D1-3 of C1-12 (Cycle: every 2 weeks)"

Trial Locations (1)

05505

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

Asan Medical Center

OTHER

NCT03698461 - Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab | Biotech Hunter | Biotech Hunter